ClinicalTrials.gg
Active, not recruitingNCT06124716COACHUpdated Apr 9, 2026

Collaboration Oriented Approach to Controlling High Blood Pressure

An interventional study of Enhanced COACH CDS Tool and Usual Care COACH CDS Tool in Hypertension and Multiple Chronic Conditions, sponsored by Oregon Health and Science University. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Hypertension is a significant contributor to poor cardiovascular outcomes. Self-management support tools can increase patient behaviors to improve blood pressure. The investigators created a clinical decision support app, called COACH, to integrate home blood pressure data and goals into EHR reporting and workflow with communications informed by behavioral economics principles to support shared decision-making. The study aims to measure the effectiveness of the COACH intervention in a pragmatic multi-site randomized trial in a primary care setting.

Read the detailed description

This protocol addresses the challenge of implementing scalable, interoperable clinical decision support (CDS) and the patient-centered outcome of avoiding heart attacks and strokes through high blood pressure control in the setting of multiple chronic illnesses. It leverages substantial extant work to build patient-centered CDS for high blood pressure, electronic care planning and health coaching at scale, implementing and testing these tools in new primary care settings. This protocol implements a new patient-facing CDS across multiple clinic sites spanning three major health systems and in the nation's two leading EHR vendor platforms. Controlling blood pressure is a singularly important goal; nearly 50% of adults in health care have high blood pressure, which increases their risk of heart attack and stroke. However, managing blood pressure requires navigation within a narrow therapeutic index, where overtreatment leads to substantial complications, including kidney damage, low blood pressure, falls, and mood disorders. Balancing treatment to reduce risk while avoiding harm requires engaging patients directly in intensive goal setting, shared care planning around nonpharmacologic and pharmacologic treatments, and self-monitoring for effectiveness and adverse events.

Hypertension rarely occurs alone; providing clinical decision support, care planning, and self-management support in the context of multiple chronic illnesses is required.

The study team will address patient-centered needs by scaling our implemented, patient-facing CDS for eCare Planning, Collaboration Oriented Approach to Controlling High blood pressure (COACH) to 3 sites and testing whether it reduces blood pressure and risk of heart attack and stroke. To do so, we embed a diverse patient perspective into a robust, feasible, and effective CDS implementation and evaluation process by 1) capturing patient input throughout the CDS lifecycle; 2) adapting the COACH CDS to patient preferences, values, and goals; and 3) disseminating the tested FHIR-based (Fast Healthcare Interoperability Resources) patient-facing application into organizations that combines blood pressure control with relevant risk scores into an eCare Plan application and framework and implementing these patient-centered approaches in feasible, context-responsive, and effective ways. The investigators address scalability by helping organizations advance their use of patient-generated health data and patient-reported outcomes using standard implementation frameworks while producing CDS artifacts and implementation guides that can be leveraged to increase adoption beyond the work of this proposal. For interoperability, we use a standard-based, structured process that re-uses concept and value sets whenever possible while using robust techniques to develop new sets and make them available for future innovators.

To complete these goals, the study investigators leverage previous work in building standardized HBP value sets, logic, and a patient-facing FHIR tool. In this work, we have engaged in several collaborations, most notably with the CDS Connect Community, where we will upload all artifacts, but also with other AHRQ digital health efforts and with other large collaboratives, including the ACC/AHA and JNC8 guideline developers, the HL7 CPG-on-FHIR, and the eCare Planning project from NIDDK and AHRQ. The study investigators will use two frameworks to evaluate the implementation. First, adaptation in implementation science is both common and may be required for success; we explore the ways in which the 5 rights-the right information to the right person in the right intervention format through the right channel at the right time in workflow-can be adapted for key organizational needs while retaining fidelity to the goals. In addition, we consider a framework that combines usability with effectiveness for complex conditions by exploring concepts related to appropriate simplicity, prioritization, summarization, adjudication, and actionability to enhance CDS effectiveness for patient needs.

Thus, the study's specific aims are:

  1. To refine and implement a patient-facing, adaptable Blood Pressure Control CDS system in 3 diverse settings, using implementation science and patient engagement to maximize effectiveness.
  2. To evaluate the effectiveness of the application at lowering blood pressure employing a mixed methods design, with qualitative inquiry nested within a randomized controlled trial, secondary RE-AIM and social cognitive theory outcomes, and qualitative evaluation of implementations across sites.
  3. To develop robust, sharable, interoperable mechanisms, leveraging collaborations and synthesis of the implementation experience to aid in further dissemination and implementations of patient-facing CDS.
02

Conditions studied

  • Hypertension
  • Multiple Chronic Conditions

Keywords

  • Pragmatic trial
  • Primary care
  • Clinical decision support
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 550 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 696 studies on the registry; 131 are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 39 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-100 years old
  • Patient receives care at a participating primary care clinic and has been seen in the last year
  • Patient has high BP, defined as an average of 4 BPs > 140 systolic or > 90 diastolic (clinic) or > 135 OR > 85 (home)
  • Patient is enrolled in online health portal
  • Patient can communicate in English
  • Patient has been recommended by their physician who thinks the patient would benefit from a home blood pressure monitoring program.

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant at the time of consent
  • Patient who, in the opinion of the primary care clinician, has severe cognitive impairment
  • Patient is on hospice care and/or has a of less than 2 years
  • Patient has end stage renal disease
  • Patient for whom tight blood pressure control presents a greater risk, such as those with a history of adverse events from hypertension treatment (falls, dizziness, electrolyte disturbances, hypotension, active heart failure)
  • Patient has any other disease or disorder that in the opinion of the investigator or the patient's primary care clinician, could put participants at risk and affect trial results, or hinder participation will exclude them from participating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Enhanced COACH

    Enhanced blood pressure management recommendations that use cognitive and behavioral science to increase the likelihood of self-management goal setting to lower blood pressure. The CDS tool allows participant access to BP visualizations, reminders, and affectively tailored messaging about blood pressure management.

    Other: Enhanced COACH CDS Tool

  • Active comparator
    Usual Care COACH

    Equivalent of usual care delivered through the CDS tool: Blood pressure management with basic information, reduced reminders, and no affective alerts.

    Other: Usual Care COACH CDS Tool

Interventions

  • OtherEnhanced COACH CDS Tool

    CDS tool with features to promote high blood pressure management

  • OtherUsual Care COACH CDS Tool

    CDS tool with limited features to promote high blood pressure management

06

What researchers measure

Primary outcomes

  1. Blood Pressure Control

    Percent of participants at or below 140/90 (office BP) or 135/85 (home BP) average.

    Time frame: Up to 6 months

Secondary outcomes

  1. Reduction in Systolic and/or Diastolic Blood Pressure

    Percent of participants displaying a decrease in systolic and/or diastolic blood pressure readings over the 6-month course of measurement

    Time frame: Up to 6 months

  2. Demographic factors contributing to blood pressure control

    Age- and socioeconomic status-reported participant data

    Time frame: Up to 6 months

  3. COACH Application System Usability Evaluation

    Participant assessment of application using the System Usability Scale questions using 4-point scale for 10 agreement questions where low scores indicate less agreement and high scores are higher agreement of usability of the application

    Time frame: Up to 6 months

  4. Participant report of health behaviors including Self Efficacy, Social Support, Outcome Expectations and Self-regulation

    Participant self-report of factors related to health beliefs using 10-point sliding scale for 25 agreement questions where low scores indicate less agreement and high scores are higher agreement of aspects of health beliefs

    Time frame: 2 months, 6 months

07

Study locations

3 sites
08

References and documents

Publications

  • Dorr DA, Montgomery E, Ghumman AJ, Michaels L, Rolbiecki A, Canfield S, Shaffer V, Johnson B, Lockwood M, Ghosh P, Martinez W, Koopman R; COACH Consortium. Study protocol: Collaboration Oriented Approach to Controlling High blood pressure (COACH) in adults - a randomised controlled trial. BMJ Open. 2024 Jul 8;14(7):e085898. doi: 10.1136/bmjopen-2024-085898. PubMed 38977368 ↗

Individual participant data

Plan to share: Yes — We will make all materials available as open source documents and CDS artifacts on our GitHub site, on the content implementation guide, on AHRQ's CDS Connect Community, and elsewhere as directed. We will publish the application on the GitHub site as open source. We will share all resources and work with all committees to find conferences, journals, and other opportunities to discuss dissemination.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06124716
Responsible party
David Dorr (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Nov 9, 2023
Start date
Jan 12, 2024
Primary completion
May 31, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

David Dorr, MD, MS, FACMI, FAMIA
principal investigator · Oregon Health and Science University
Richelle Koopman, MD
principal investigator · University of Missouri-Columbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion